Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HRMY stock price vs LOW: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LOW's multiple
Needs LOW P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · LOW FY 2026 (ended Jan 30, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 2.13x · EV / EBITDA 7.28x
Capital structure 74% equity / 26% debt · EV / Revenue 1.78x · EV / EBITDA 13.99x
LOW carries the larger enterprise value at $153.20B against $1.85B; LOW trades on the lower EV / Revenue multiple (1.78x vs 2.13x); HRMY on the lower EV / EBITDA (7.28x vs 13.99x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
LOWES COMPANIES INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.19x
-4.02x
Net debt / EBITDA
Leverage against operating earnings
-2.41x
3.51x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$1.35B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
HOME DEPOT, INC.
HRMY vs HD
SHERWIN WILLIAMS CO
HRMY vs SHW
WILLIAMS SONOMA INC
HRMY vs WSM
Tractor Supply Company
HRMY vs TSCO
$163.66M
$39.82B
Edwyn research
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HRMY can sustain 20%+ revenue growth and high-70% gross margins, then the current price looks attractive relative to the $52.02 implied P/E value because HRMY already trades below that level while showing stronger profitability than LOW.
HRMY trades at 13.8x P/E versus LOW at 19.2x, yet the valuation setup is mixed because HRMY also commands a higher P/S multiple and a lower EV/EBITDA multiple. The current $37.28 price sits below the historical band and DCF range, while still meaningfully below the $52.02 implied price.
Supporting Metrics
